Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

View Full Paper
Ask AI
Bookmark
Share

Authors

CPCécile PizotRHRoch HouotTGThomas Gastinne

Discussion

Loading...

Member takes

Overview

Real-world study demonstrates CAR T-cell therapy yields high response rates and manageable neurotoxicity in secondary CNS lymphomas, suggesting promising therapeutic potential.

Key Points

  • Complete response rate reached 66% following CAR T-cell therapy in a cohort of secondary CNS lymphomas.
  • After 18 months, progression-free survival was 37%, with a low relapse rate indicating sustained efficacy.
  • Propensity score method compared CNS lymphoma patients to systemic lymphoma patients, showing no significant differences in neurotoxicity rates.
  • Overall survival at 18 months was 53%, highlighting the treatment's potential benefit for hematologic malignancies.

Cite This Study

Pizot et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3a0https://doi.org/10.1182/blood-2025-1012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  2. 2P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025
  3. 3Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025
  4. 4Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy2025
  5. 5P14.05.B CAR T-CELL THERAPY DOES NOT LEAD TO MEDIUM-TERM NEUROCOGNITIVE DETERIORATION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMAS. A LOC NETWORK STUDY2025